Citoxlab ups pharmacokinetics, metabolism assessment services with CRO acquisition

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)
The non-clinical contract research organization (CRO) Citoxlab Group has acquired Solvo Biotechnology, a CRO specializing in drug transporters studies and the assessment of drug-drug interactions (DDI).

Solvo will retain its brand and the team of around 100 will be maintained and reinforced in the future, said Dr. Jean-Francois Le Bigot, president and CEO of Citoxlab Group, who also confirmed plans to move Solvo’s laboratories into new facilities near the University of Budapest in order to increase laboratory space.

The acquisition, terms of which we not disclosed, is expected to close within the next month, and is the third made by Citoxlab in the last 18 months.

“The acquisition of Solvo follows the acquisition of AcceLAB in 2016 and the one of Xenometrics announced in November 2017, which already boosted Citoxlab revenues growth which was 21.5% last year,”​ said Le Bigot.

Following the acquisition, Citoxlab will able to offer its customers a range of services for in vivo​ and in vitro​ assessment of pharmacokinetics and metabolism of new drug candidates, including the prediction of potential drug-drug interactions.

“The knowledge of new drug candidates’ transport is key today to predict pharmacokinetics and also to predict potential drug-drug interactions,”​ said Le Bigot. “With the ​in vitro models of transport that Solvo has developed and validated, this knowledge can be gained at an early stage in the drug development process.”

Solovo’s in vitro​ models are complementary to the in vivo​ investigations of pharmacokinetics and metabolism provided by Citoxlab research centers in France, the US, and Canada, she added.

Le Bigot explained that drug-drug interactions have become a significant public health problem. “The origin of these DDI are mainly related to interferences occurring in drug transport and/or interferences (inhibition or induction) in drug metabolism,” ​he said.

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us


View more